This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marx, N. Articles by Plutzky, J. Search for Related Content PubMed PubMed Citation Articles by Marx, N. Articles by Plutzky, J.

(Circulation Research. 1998;83:1097-1103.)
© 1998 American Heart Association, Inc.

Original Contributions

Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells

Nikolaus Marx, Uwe Schönbeck, Mitchell A. Lazar, Peter Libby, , Jorge Plutzky

From the Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School (N.M., U.S., P.L., J.P.), Boston, Mass, and the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and the Department of Genetics, University of Pennsylvania School of Medicine (M.A.L.), Philadelphia, Pa.

Correspondence to Jorge Plutzky, MD, Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115. E-mail jplutzky{at}bustoff.bwh.harvard.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Migration of vascular smooth muscle cells (VSMCs) plays an important role in atherogenesis and restenosis after arterial interventions. The expression of matrix metalloproteinases (MMPs), particularly MMP-9, contributes to VSMC migration. This process requires degradation of basal laminae and other components of the arterial extracellular matrix. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, regulate gene expression after activation by various ligands. Recent studies have suggested opposing effects of PPAR gamma (PPAR) activation on atherogenesis. The present study tested the hypotheses that human VSMCs express PPAR alpha (PPAR) and PPAR and that PPAR agonists in VSMCs modulate MMP-9 expression and activity, as well as VSMC migration. Human VSMCs expressed PPAR and PPAR mRNA and protein. Treatment of VSMCs with the PPAR ligands troglitazone and the naturally occurring 15-deoxy-^12,14-prostaglandin J₂ (15d-PGJ₂) decreased phorbol 12-myristate 13-acetate–induced MMP-9 mRNA and protein levels, as well as MMP-9 gelatinolytic activity in the supernatants in a concentration-dependent manner. Six different PPAR activators lacked such effects. Addition of prostaglandin F₂, known to limit PPAR activity, diminished the MMP-9 inhibition seen with either troglitazone or 15d-PGJ₂, further implicating PPAR in these effects. Finally, troglitazone and 15d-PGJ₂ inhibited the platelet-derived growth factor-BB–induced migration of VSMCs in vitro in a concentration-dependent manner. PPAR activation may regulate VSMC migration and expression and activity of MMP-9. Thus, PPAR activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring ligands, may act to counterbalance other potentially proatherosclerotic PPAR effects.

Key Words: gene expression • vascular smooth muscle cell • migration • peroxisome proliferator-activated receptor gamma • troglitazone

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Vascular smooth muscle cell (VSMC) migration likely contributes to both atherogenesis and restenosis, complicating interventional treatments of atherosclerosis. Migration of VSMCs into and within the intima requires the degradation of basal laminae and interstitial extracellular matrix, processes that likely involve matrix metalloproteinases (MMPs).¹ Among these, MMP-9, also known as gelatinase B, appears particularly important in migration of VSMCs after arterial injury. In situ hybridization demonstrated induction of MMP-9 mRNA in VSMCs within the first days after balloon injury in rat carotid arteries.² Furthermore, systemic administration of an MMP inhibitor reduced early migration into the intima by 97%.² Overexpression of MMP-9 occurs in vulnerable regions of human atheroma³ and in atherectomy specimens retrieved from humans with unstable coronary syndromes.⁴ Several mediators present in human atheroma, such as interleukin (IL)-1,⁵ tumor necrosis factor-, and CD40 ligand⁶ can induce MMP-9 expression in VSMCs. The complexity of governing the balance of MMP activity is underscored by the presence of a family of inhibitors of MMP activity, proteins known as tissue inhibitors of MMP (TIMPs). However, regulatory signals directly inhibiting MMP-9 gene expression in VSMCs remain poorly understood.

Troglitazone, a new antidiabetic agent, reduces arterial injury-induced intimal hyperplasia, as well as migration and proliferation of rat VSMCs.⁷ Troglitazone acts as a ligand for peroxisome proliferator-activated receptor gamma (PPAR),⁸ one of three members (alpha, delta, and gamma) of a family of ligand-activated nuclear receptor transcription factors. With ligand binding, PPARs form heterodimers with the retinoic X receptor and bind to PPAR response elements in the promoter region of specific target genes, thus regulating their expression.^{9 10 11 12} PPAR appears to interact with various fatty acids and eicosanoid derivatives, whereas PPAR ligands, in addition to troglitazone, include the naturally occurring prostaglandin D₂ metabolite, 15-deoxy-^12,14-prostaglandin J₂ (15d-PGJ₂).^{13 14}

Macrophages in human atheroma express PPAR.^{15 15A} In vitro studies have revealed that PPAR activation inhibits expression of proinflammatory genes as well as macrophage scavenger receptor A and inducible nitric oxide synthetase genes in cells of the monocyte lineage.^{16 17} PPAR activation also decreases MMP-9 expression and gelatinolytic activity in these same cells.¹⁵ In contrast, other recent studies implicate PPAR activation in promoting atherogenesis. Tontonoz et al¹⁸ and Nagy et al¹⁹ report that the scavenger receptor CD36 is a PPAR-regulated gene, that oxidized LDL is a naturally occurring PPAR ligand, and that PPAR activation contributes to monocyte differentiation into foam cells. Given the role of VSMCs in atherosclerosis and restenosis, we hypothesized that PPAR effects in VSMCs might oppose potentially proatherogenic actions induced by PPAR activation in monocyte/macrophages. Specifically, we tested whether VSMCs express PPAR and if so, whether PPAR activation in these cells inhibits MMP-9 expression and activity. Furthermore, we investigated if PPAR ligands might inhibit human VSMC migration.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell Culture
Human VSMCs were isolated from the tunica media human saphenous veins and cultured in DMEM (BioWhittaker, Walkersville, Md) with 1% glutamine (Sigma Chemical Co, St. Louis, Mo), 1% penicillin-streptomycin (Sigma), and 10% FCS. The cells were identified by their typical growth pattern and by immunofluorescence with anti–-actin monoclonal antibodies (>99% positive cells). These experiments used cells at passages two to five. Cells were cultured in serum-free medium supplemented with insulin and transferrin (IT-medium) for 24 hours and then stimulated with phorbol 12-myristate 13-acetate (PMA) (50 mg/L) in the presence or absence of different activators of PPAR (docosahexanoic acid, eicosapentaenoic acid, fenofibrate, gemfibrozil, clofibrate [all from Sigma], and WY 14643 [Biomol, Plymouth Meeting, Pa]), or of PPAR (troglitazone [provided by Parke-Davis, Ann Arbor, Mich] and 15d-PGJ₂ [Calbiochem, La Jolla, Calif]). Viability of the cells after stimulation was >95% as tested by trypan blue staining and a lactate dehydrogenase assay on cell supernatants (Sigma).

RNA Extraction and Reverse Transcriptase–Polymerase Chain Reaction (RT-PCR)
Total RNA from VSMCs was isolated by the single-step guanidinium thiocyanate-phenol-chloroform method using RNAzol (Tel-Test, Friendswood, Tex). Two micrograms of total RNA was reverse-transcribed into cDNA with 1U/mL reverse transcriptase (Superscript, Gibco-BRL, Gaithersburg, Md) at 37°C for 1 hour in standard buffer. For the amplification of PPAR and PPAR cDNA, the following oligonucleotide primers were designed: for PPAR from nucleotide +200 to +476 (a 276-bp fragment): sense primer 5'-AGATTTCGCAATCCATCGGC-3'; antisense primer 5'-GCGTGGACTCCGTAATGATA-3'; for PPAR from nucleotide +235 to +708 (a 473-bp fragment): sense primer 5'-TCTCTCCGTAATGGAAGACC-3'; antisense primer 5'-CCCCTACAGAGTATTACG-3'. For the amplification of GAPDH cDNA, 2 oligonucleotide primers were used (a 452-bp fragment): sense primer 5'-ACCACAGTCCATGCCATCAC-3'; antisense primer 5'-TCCACCACCCTGTTGCTGTA-3'. The PCR reaction was carried out in a standard buffer (Gibco-BRL) with 200 ng of each primer (IDT, Coralville, Iowa), 33 mmol/L MgCl₂, and 0.5 U Taq polymerase (Gibco-BRL) for 30 cycles. PCR products (10 mL/25 mL) were analyzed on a 2% agarose gel.

Northern Blot Analysis
Total RNA (5 µg) was used for standard Northern blotting. After electrophoresis, RNA was transferred to a nylon membrane (ICN, Irvine, Calif) in 20x SSC by using capillary blotting overnight. Blots were UV-cross-linked, prehybridized (50% formamide, 5x Denhardt's solution, 5x SSC, 0.5% SDS, and 20 mmol/L salmon sperm DNA), and hybridized in the same buffer with a radiolabeled (-³²P dCTP) probe for human MMP-9. The probe was generated by RT-PCR from RNA of PMA-treated U937 cells using sense primer 5'-GGCGCTCATGTACCCTATGT-3'and antisense primer 5'-TCAAAGACCGAGTCCAGCTT-3' (a 468-bp fragment) (IDT). The membranes were washed at 60°C in 1% SDS/2x SSC and autoradiographed with Kodak X-OMAT film at -70°C with an intensifying screen.

Preparation of Nuclear and Cytosolic Extracts and Western Blot Analysis
For Western blot analysis, positive controls were generated by transiently transfecting a PPAR (pCMX-PPAR) or PPAR expression construct (pCMX-PPAR)²⁰ (both generous gifts from Dr Bruce Spiegelman, Dana Farber Cancer Institute, Boston, Mass) into human skin fibroblasts using lipofectamine (Gibco-BRL) according to the manufacturer's protocol. Nuclear and cytosolic extracts of VSMCs were prepared separately. Cells were lysed in 10 mmol/L HEPES (pH 7.9), 1.5 mmol/L MgCl₂, 10 mmol/L KCl, and 0.5% NP-40. Nuclei were pelleted at 13 000g for 5 minutes, and the resulting supernatant was used as the cytosol fraction. Nuclei were lysed in 20 mmol/L HEPES (pH 7.9), 1.5 mmol/L MgCl₂, 420 mmol/L NaCl, and 0.2 mmol/L EDTA. After centrifugation at 13 000g for 5 minutes, the supernatant was diluted in equal volume of 20 mmol/L HEPES (pH 7.9), 100 mmol/L KCl, 0.2 mmol/L EDTA, and 20% glycerol and used as nuclear extract. Protein concentration of nuclear and cytosolic extracts was determined colorimetrically (Pierce, Rockford, Ill). Processed samples were applied to 10% SDS gels and transferred to nitrocellulose membranes (Millipore, Bedford, Mass) using semidry blotting, as described previously.⁶ Membranes were blocked overnight in TBS-Tween with 5% nonfat dry milk and incubated with goat anti-human PPAR or goat anti-human PPAR antibodies (mAbs) (Santa Cruz, San Diego, Calif) for 1 hour. After washing, membranes were stained with horseradish peroxidase–conjugated rabbit anti-goat mAbs. Antigen detection was performed with a chemiluminescent detection system (NEN, Boston, Mass). Similar methods were used to perform Western blot analysis on MMP-9 or MMP-2 in VSMC supernatants using the respective anti-human mAbs (Oncogene Research, Cambridge, Mass). For the analysis of TIMP-1 and TIMP-2 in VSMC supernatants, we used anti-human TIMP-1 and anti-human TIMP-2 mAbs (Oncogene Research).

Substrate Gel Zymography
Human VSMCs were stimulated for 24 hours with PMA (50 mg/L) in the presence or absence of different PPAR or PPAR activators. Culture supernatants were concentrated (10x), and the gelatinolytic activity of secreted MMP-9 was analyzed by zymography on gelatin-containing polyacrylamide gels.⁶ After washing in 2.5% Triton X-100, gels were incubated overnight at 37°C in 50 mmol/L Tris-HCl (pH 7.4), containing CaCl₂ and 0.05% Brij 35. Gels were stained in 0.1% Brilliant Blue G–Colloidal (Sigma), 10% acetic acid, and 40% methanol for 2 hours and destained in 10% acetic acid and 40% methanol. Proteins having gelatinolytic activity were visualized as clear zones in a blue gel. Densitometric analysis was performed using NIH Image 1.6 software program, and the results were normalized to the band of constitutively expressed MMP-2.

In some experiments, VSMCs were stimulated with PMA, troglitazone, or 15d-PGJ₂ and prostaglandin F₂ (PGF₂), an agent known to inhibit PPAR activation.²¹

Migration Assay
Migration of VSMCs was investigated through the use of a standard in vitro wound assay. VSMCs were grown in 6-well plates to confluence, and after 24 hours of culture in IT-medium, a reusable template was used to create a standard wound (30 mm). Cells were then stimulated with platelet-derived growth factor (PDGF)-BB (50 µg/L) in the presence or absence of troglitazone or 15d-PGJ₂, and wound closure rates followed. A reference point was created on the bottom of the plate in the field of the wound using direct microscopic visualization. This procedure permitted photographing the identical spot each time. The remaining cell-free area was determined via microphotography performed immediately after injury as well as 6 hours after stimulation. Differences were analyzed using NIH Image 1.6 software program, and the results were expressed as percent of migration compared with cultures stimulated with PDGF lacking any PPAR activators.

Statistical Analysis
Results of the experimental studies are reported as mean±SEM. Differences were analyzed by paired Student t test. A P value <0.05 in the 2-tailed test was regarded as significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Human VSMCs Express PPAR and PPAR mRNA and Protein
Cultured human VSMCs express PPAR and PPAR mRNA as detected by RT-PCR products of the predicted size (Figure 1A). Western blot analysis revealed PPAR and PPAR protein expression in the nuclear fraction, whereas neither protein was detected in the cytosol fraction (Figure 1B). The identity of the bands was confirmed by its apparent molecular weight and its comigration with the signal from nuclei of PPAR- or PPAR-transfected fibroblasts. Nuclei from untransfected fibroblasts exhibit no similar signal (data not shown).

View larger version (41K): [in this window] [in a new window]   Figure 1. Human VSMCs express PPAR and PPAR mRNA and protein. A, RT-PCR of total RNA from 3 different VSMC preparations with PPAR-, PPAR-, and GAPDH-specific primers. A 100-bp ladder (MW) and the control consisting of RT-PCR reactions lacking reverse transcriptase (Co) are also shown. B, Western blot analysis of PPAR and PPAR protein expression in nuclear extracts (Nu) of human VSMCs reveals immunoreactive protein of the appropriate size. Neither PPAR nor PPAR is detected in the cytosolic fraction (Cy). Immunoreactive proteins comigrate with a band observed with nuclear extracts of PPAR- or PPAR-transfected human skin fibroblasts (+). Three independent experiments showed similar results.

PPAR but not PPAR Activators Decrease Both Secreted MMP-9 Protein Levels and Gelatinolytic Activity in VSMCs
To investigate whether PPAR activation in VSMCs regulates MMP-9 protein expression and gelatinolytic activity, we stimulated human VSMCs with PMA in the presence or absence of PPAR or PPAR activators and performed Western blot analysis as well as gelatin substrate zymography on supernatants. As previously reported, quiescent VSMCs secreted MMP-9 at very low levels,⁶ and stimulation with PMA markedly augmented MMP-9 protein levels in the supernatant. None of the PPAR activators used affected MMP-9 protein expression or gelatinolytic activity (Figure 2A). In contrast, treatment of PMA-stimulated VSMCs with the PPAR activators troglitazone or 15d-PGJ₂ decreased MMP-9 protein levels in a concentration-dependent manner (Figure 3A, upper panels). Moreover, gelatin zymography of the supernatants from VSMCs so treated revealed a decrease of MMP-9 gelatinolytic activity (Figure 3A, middle panels), with a maximal reduction to 44±3% at 10 µmol/L troglitazone (P<0.01; n=3) and 21±3% at 10 µmol/L 15d-PGJ₂ (P<0.01; n=3) compared with PMA-stimulated VSMCs (Figure 3A, lower panels).

View larger version (72K): [in this window] [in a new window]   Figure 2. A, PPAR activators do not affect PMA-induced MMP-9 expression and gelatinolytic activity in VSMCs. VSMCs were cultured for 24 hours in serum-free medium and then stimulated with PMA (50 mg/L) in the presence or absence of 10 µmol/L docosahexanoic acid (DHA), 10 µmol/L eicosapentaenoic acid (EPA), 100 µmol/L WY 14643 (WY), 100 µmol/L fenofibrate (fenof), 100 µmol/L gemfibrozil (gemf), or 100 µmol/L clofibrate (clof). Culture supernatants were collected after 24 hours and used for MMP-9 Western blot analysis (upper panel) or gelatin zymography (middle panel). Western blot analysis of MMP-2 expression is also shown (lower panel). The identity of the 72-kDa band as MMP-2 in the zymography was confirmed by depletion of MMP-2 from VSMC supernatant with anti–MMP-2 mAbs (insert: -), whereas the pellet continued to show MMP-2 at 72 kDa (insert: +). B, PPAR activators do not affect TIMP-1 or TIMP-2 expression in VSMCs. Cells were treated as described above, and Western blot analysis for TIMP-1 and TIMP-2 in VSMC supernatants was performed.

View larger version (56K): [in this window] [in a new window]   Figure 3. PPAR activators troglitazone and 15d-PGJ2 inhibit MMP-9 expression and gelatinolytic activity in human VSMCs in a concentration-dependent manner. A, Western blot analysis (upper panels) and gelatin zymography (middle panels) on supernatants from human VSMCs after treatment with PMA (50 mg/L) in the presence or absence of troglitazone (trogl) or 15d-PGJ2 at different concentrations. Lower panel, Densitometric analysis of the MMP-9 gelatinolytic activity in zymograms (solid bars) or MMP-9 protein levels in Western blots (open bars) are shown as percent of PMA-stimulated cells. Results are presented as mean±SEM (n=3). B, PPAR activators troglitazone (trogl) or 15d-PGJ2 (both 10 µmol/L) do not affect the expression of TIMP-1 and TIMP-2 in VSMC supernatants as shown by Western blot analysis. C, Northern blot analysis (upper panel) of total RNA of human VSMCs treated with PMA (50 mg/L) in the presence or absence of troglitazone (trogl) or 15d-PGJ2 (both 10 µmol/L). Ethidium bromide staining of the gel shows similar loading in all lanes (lower panel). Similar results were seen in 3 independent experiments.

Neither PPAR activators nor PPAR agonists affected the constitutively expressed 72-kDa gelatinase (MMP-2), as shown by zymography (Figures 2A and 3) and Western blot (Figure 2A, lower panel) analysis. To confirm the identity of the lytic band at 72 kDa in the zymography as being MMP-2, we performed immunoprecipitation and immunodepletion experiments on supernatants from PMA-treated VSMCs. As shown in the insert in Figure 2A, the band corresponding to MMP-2 could be depleted from the supernatant with anti–MMP-2 antibodies, whereas the pellet continues to show a 72-kDa signal. Treatment of VSMCs with either PPAR or PPAR activators in the absence of PMA did not change MMP-9 protein levels or gelatinolytic activity in supernatants (data not shown). Determination of lactate dehydrogenase in the supernatants revealed no significant differences between the samples, indicating that the effects observed did not result from cell death (data not shown).

Western blot analysis for TIMP-1 and TIMP-2 on supernatants from unstimulated (data not shown) or PMA-stimulated VSMCs (Figures 2B and 3B) revealed no changes after treatment with PPAR or PPAR activators.

PPAR Activation Decreases MMP-9 mRNA in VSMCs
Northern blot analysis of PMA-stimulated VSMCs treated with or without PPAR activators for 18 hours demonstrated a marked reduction of MMP-9 mRNA (size, 2.3 kb) levels by either troglitazone or 15d-PGJ₂ (Figure 3C, upper panel). Ethidium bromide staining of the gels showed equivalent loading in each lane (Figure 3C, lower panel).

Inactivation of PPAR Through PGF₂ Diminishes the Inhibition of MMP-9 Expression by Troglitazone and 15d-PGJ₂
To determine whether PPAR mediates the effects of troglitazone and 15d-PGJ2, we performed similar experiments in the presence of PGF₂, an agent known to inactivate PPAR by causing its phosphorylation.²¹ Addition of PGF₂ (200 nmol/L) diminished the inhibitory effect of troglitazone or 15d-PGJ₂ on PMA-induced MMP-9 expression (Figure 4A) and gelatinolytic activity (Figure 4B). PGF₂ alone had no effect on MMP-9 protein expression or gelatinolytic activity.

View larger version (28K): [in this window] [in a new window]   Figure 4. Inhibition of PPAR through PGF2 diminishes the inhibitory effect of troglitazone and 15d-PGJ2 on MMP-9 expression and gelatinolytic activity in VSMCs. Western blot (A) and gelatin zymography (B) on supernatants of human VSMCs after treatment for 24 hours with PMA (50 mg/L), troglitazone (10 µmol/L) (trogl), or 15d-PGJ2 (10 µmol/L) in the presence or absence of 200 nmol/L/L PGF2. PGF2 alone had no effect on MMP-9 gelatinolytic activity. Similar results were seen in 3 independent experiments.

Troglitazone and 15d-PGJ₂ Inhibit PDGF-BB–Induced Migration of VSMCs
To explore whether PPAR activation directly affects PDGF-BB–induced VSMC migration, we performed an in vitro wound closure assay. Treatment of human VSMCs with troglitazone significantly decreased the PDGF-BB–induced migration to 39±3% at 5 µmol/L and to 34±12% at 10 µmol/L (P<0.05), respectively (Figure 5). 15d-PGJ₂ reduced the migration significantly to 42±7% at 5 µmol/L and to 25±6% at 10 µmol/L 15d-PGJ₂ (P<0.05), respectively (Figure 5). Medium with solvent alone had no influence on VSMC migration (data not shown).

View larger version (12K): [in this window] [in a new window]   Figure 5. PPAR activators inhibit the PDGF-BB–induced migration of human VSMCs. Confluent human VSMCs were cultured in serum-free medium for 24 hours, wounded with a cell scraper, and then stimulated with PDGF-BB (50 mg/L) in the presence or absence of troglitazone or 15d-PGJ2 at concentrations indicated. Results (n=3) were expressed as percent of migration compared with cells stimulated with PDGF-BB alone. Results were replicated in 3 experiments.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The present study reports expression of both PPAR and PPAR by human VSMCs. Although PPAR activation had no effect on MMP-9 expression, stimulation of PPAR inhibited MMP-9 mRNA and protein expression, gelatinolytic activity, and PDGF-BB–induced migration of human VSMCs. Neither PPAR nor PPAR activators appear to influence TIMP expression.

The absence of an effect of PPAR agonists on MMP-9 expression or enzymatic activity could be explained by either low PPAR levels in these cells or a lack of transcriptional regulation by PPAR on this gene. Our data showing approximately similar levels of PPAR and PPAR in VSMCs, within the limitations of RT-PCR and Western blotting techniques, argue against low PPAR levels as an explanation for these findings. Furthermore, while this article was in review, Staels et al²⁰ also found that PPAR and PPAR were present in VSMCs, at a modestly higher level of PPAR than PPAR under the conditions of their experiments. These investigators also reported that PPAR, but not PPAR, agonists inhibited the IL-1–induced production of IL-6 and prostaglandin and the expression of the cyclooxygenase-2 gene. As such, although PPAR appears to be functionally active in VSMCs, our work suggests that it is not involved in MMP-9 regulation.

In contrast, PPAR activators do inhibit MMP-9 expression and gelatinolytic activity in stimulated VSMCs. Our data suggest PPAR activation as the mechanism for the effects of these activators. Troglitazone is a synthetic compound known to have a high affinity for PPAR as evidenced by ligand binding assays.⁸ 15d-PGJ₂ also has significant binding capacity to PPAR, although it may also have some activity on other PPAR isoforms.^{13 22} However, because none of 6 established PPAR activators^{22 22A} demonstrated any effect on MMP-9, PPAR activation by 15d-PGJ₂ would seem to be an unlikely explanation for our findings. Furthermore, the ability to reverse the effects of troglitazone and 15d-PGJ₂ on MMP-9 by PGF₂ costimulation also supports that these agonists are acting through PPAR; PGF₂ has been shown to induce inhibitory phosphorylation of PPAR by activation of mitogen-activated protein kinase.²¹

The mechanism through which PPAR activators inhibit MMP-9 expression is likely to be transcriptional, although posttranscriptional modulation cannot be ruled out. Certainly, nuclear hormone receptors, including PPARs, negatively regulate expression of other genes. The transcriptional suppression of MMP-9 could be due to a negative PPAR-response element, as previously described for the apolipoprotein A-1 gene²³ and for thyroid hormone regulation of thyroid-stimulating hormone.²⁴ Alternatively, inhibitory effects might occur independent of a PPAR binding site, through competitive binding and "squelching" of transcriptional coactivators by liganded PPAR. This has been suggested as the mechanism of negative cross talk between other nuclear receptors and activator protein-1²⁵ as well as other transcription factors.^{26 27}

The expression of PPARs in VSMCs, and its regulation of MMP-9 expression and activity, and VSMC migration have potentially important implications for atherosclerosis. Matrix degradation by MMPs and medial VSMC movement into the intima occur early during intimal hyperplasia in injured rat arteries.²⁸ Similar processes are very likely to contribute to human atherogenesis. Interestingly, troglitazone inhibits intimal thickening after arterial injury in rats,⁷ a process that might be influenced by the MMP-9 effects described in the present study.

Beyond the part of PPAR in VSMC biology is the question of its role in the pathology of the arterial wall. Several lines of evidence would suggest an antiatherosclerotic effect of PPAR activation: inhibition of MMP-9 in VSMCs and monocyte/macrophages, decreased expression of cytokines and inducible nitric oxide synthetase,^{16 17} and decreased LDL oxidation in response to troglitazone.²⁹ Furthermore, preliminary findings of decreased intimal and medial carotid thickening in diabetic patients treated with troglitazone also suggest that PPAR activation might limit atherogenesis.³⁰

In contrast, Tontonoz et al¹⁸ and Nagy et al¹⁹ recently reported that oxidized LDL increases scavenger receptor (CD36) expression via direct PPAR binding and transcriptional activation. They found, as did we, high levels of PPAR in lesional macrophages, although our data also suggested inhibition of macrophage MMP-9 expression via PPAR, which might limit atherosclerosis. The evidence to date in monocyte/macrophages might suggest complex regulatory effects of PPAR, with mediation of macrophage development and oxidized LDL signaling on one hand and decreased MMP-9 and inflammatory cytokine production on the other. Reconciling these findings with the overall benefits seen with troglitazone in the clinical setting^{31 32} might suggest PPAR effects in other arterial wall cells that limit the atherogenic response. The data in the present study suggest that PPAR activation in human VSMCs might provide one such counterbalancing antiatherogenic mechanism.

	Acknowledgments

 
This work was supported in part by grants from the Deutsche Forschungsgemeinschaft to Dr Nikolaus Marx (MA 2047/1-1), the NIH to Dr Mitchell Lazar (P01 DK49210 and RO1 DK49780), and the NIH/NHLBI to Dr Peter Libby (HL48743) and to Dr Jorge Plutzky (HL03107). The Vascular Medicine and Atherosclerosis Unit of Brigham and Women's Hospital has received unrestricted grants from Parke-Davis. Drs Plutzky and Libby are also consultants and speakers for Parke-Davis. We thank Dr Marisia Muszynski (Brigham and Women's Hospital) for her skillful assistance.

	Footnotes

 
This manuscript was sent to François M. Abboud, Consulting Editor, for review by expert referees, editorial decision, and final disposition.

Received April 22, 1998; accepted September 9, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Galis Z, Muszynski M, Sukhova G, Simon-Morrissey E, Unemori E, Lark M, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix degradation. Circ Res. 1994;75:181–189.[Abstract/Free Full Text]

2. Bendeck M, Zempo N, Clowes A, Galardy R, Reidy M. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539–545.[Abstract/Free Full Text]

3. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503.

4. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92 kD gelatinase in human coronary atherosclerotic lesions. Circulation. 1995;91:2125–2131.[Abstract/Free Full Text]

5. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335–342.

6. Schönbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy J-Y, Fabunmi R, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes. Circ Res. 1997;81:448–454.[Abstract/Free Full Text]

7. Law R, Meehan W, Xi X, Graf K, Wuthrich D, Coats W, Faxon D, Hsueh W. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897–1905.[Medline] [Order article via Infotrieve]

8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953–12956.[Abstract/Free Full Text]

9. Zhu Y, Qi C, Korenberg J, Chen X, Noya D, Rao M, Reddy J. Structural organization of mouse peroxisome proliferator-activated receptor (mPPAR) gene: alternative promotor use and different splicing yield two mPPAR isoforms. Proc Natl Acad Sci U S A.. 1995;92:7921–7925.[Abstract/Free Full Text]

10. Schoonjans K, Peinado-Onsurbe J, Lefebvre A, Deeb S, Staels B, Auwerx J. PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336–5348.[Medline] [Order article via Infotrieve]

11. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159–166.[Medline] [Order article via Infotrieve]

12. Fajas L, Auboeuff D, Raspe E, Schoonjans K, Lefebvre A-M, Saladin R, Najib J, Laville M, Fruchart J-C, Deeb S, Vidal-Puig A, Flier J, Briggs M, Staels B, Vidal H, Auwerx J. The organization, promotor analysis, and expression of the human PPAR gene. J Biol Chem. 1997;272:18779–18789.[Abstract/Free Full Text]

13. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J₂ metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell. 1995;83:813–819.[Medline] [Order article via Infotrieve]

14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812.[Medline] [Order article via Infotrieve]

15. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR: differentiation-dependent PPAR expression and reduction of MMP-9 activity through PPAR activation in mononuclear phagocytes. Am J Pathol. 1998;153:17–23.[Abstract/Free Full Text]

15A. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614–7619.[Abstract/Free Full Text]

16. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82.[Medline] [Order article via Infotrieve]

17. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86.[Medline] [Order article via Infotrieve]

18. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–252.[Medline] [Order article via Infotrieve]

19. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229–240.[Medline] [Order article via Infotrieve]

20. Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Torra I, Delerive P, Fadel A, Chinetti G, Fruchart J-C, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth muscle cells is inhibited by PPAR but not by PPAR activators. Nature. 1998;393:790–793.[Medline] [Order article via Infotrieve]

21. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998;273:1855–1858.[Abstract/Free Full Text]

22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with the peroxisome proliferator-activated receptor alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318–4323.[Abstract/Free Full Text]

22A. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 1993;90:2160–2164.[Abstract/Free Full Text]

23. Vu-Dac N, Schoonjans K, Laine B, Fruchart J, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269:31012–31018.[Abstract/Free Full Text]

24. Rentoumis A, Chatterjee V, Madison L, Datta S, Gallagher G, Degroot L, Jameson J. Negative and positive transcriptional regulation by thyroid hormone receptor isoforms. Mol Endocrinol. 1990;4:1522–1531.[Abstract/Free Full Text]

25. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev. 1993;14:651–658.[Abstract/Free Full Text]

26. Schwarz E, Reginato M, Shao D, Krakow S, Lazar M. Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell Biol. 1997;17:1552–1561.[Abstract]

27. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S, Heyman R, Rose D, Glass C, Rosenfeld M. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996;85:403–414.[Medline] [Order article via Infotrieve]

28. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327–333.[Medline] [Order article via Infotrieve]

29. Cominacini L, Garbin U, Fratta-Pasini A, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi A, Lo Cascio V, Ferranini E. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentrations in NIDDM patients. Diabetes. 1998;47:130–133.[Abstract]

30. Minamikawa J, Yamauchi M, Innoue D, Koshiyama H. Another potential use of troglitazone in non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1041–1042.[Free Full Text]

31. Schwartz S, Raskin P, Fonseca V, Graveline J. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861–866.[Abstract/Free Full Text]

32. Inzuchi S, Maggs D, Spollet G, Page S, Rife F, Walton V, Shulman G. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med. 1998;338:867–872.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. Jones, R. Deb, E. Torsney, F. Howe, M. Dunkley, Y. Gnaneswaran, D. Gaze, H. Nasr, I. M. Loftus, M. M. Thompson, et al. Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms Circulation, June 23, 2009; 119(24): 3125 - 3132. [Abstract] [Full Text] [PDF]

				C.-C. Szeto and K.-M. Chow THIAZOLIDINEDIONES IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., May 1, 2009; 29(3): 248 - 251. [Full Text] [PDF]

				D. Meredith, M. Panchatcharam, S. Miriyala, Y.-S. Tsai, A. J. Morris, N. Maeda, G. A. Stouffer, and S. S. Smyth Dominant-Negative Loss of PPAR{gamma} Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling Arterioscler. Thromb. Vasc. Biol., April 1, 2009; 29(4): 465 - 471. [Abstract] [Full Text] [PDF]

				J. D. Alexis, N. Wang, W. Che, N. Lerner-Marmarosh, A. Sahni, V. A. Korshunov, Y. Zou, B. Ding, C. Yan, B. C. Berk, et al. Bcr Kinase Activation by Angiotensin II Inhibits Peroxisome Proliferator-Activated Receptor {gamma} Transcriptional Activity in Vascular Smooth Muscle Cells Circ. Res., January 2, 2009; 104(1): 69 - 78. [Abstract] [Full Text] [PDF]

				N. Wang, J. D. Symons, H. Zhang, Z. Jia, F. J. Gonzalez, and T. Yang Distinct Functions of Vascular Endothelial and Smooth Muscle PPAR{gamma} in Regulation of Blood Pressure and Vascular Tone Toxicol Pathol, January 1, 2009; 37(1): 21 - 27. [Abstract] [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				S. Delbosc, M. Glorian, A.-S. Le Port, G. Bereziat, M. Andreani, and I. Limon The Benefit of Docosahexanoic Acid on the Migration of Vascular Smooth Muscle Cells Is Partially Dependent on Notch Regulation of MMP-2/-9 Am. J. Pathol., May 1, 2008; 172(5): 1430 - 1440. [Abstract] [Full Text] [PDF]

				S. Z. Duan, M. G. Usher, and R. M. Mortensen Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature Circ. Res., February 15, 2008; 102(3): 283 - 294. [Abstract] [Full Text] [PDF]

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]

				J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF]

				W. T. Gerthoffer Mechanisms of Vascular Smooth Muscle Cell Migration Circ. Res., March 16, 2007; 100(5): 607 - 621. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				M. Joner, A. Farb, Q. Cheng, A. V. Finn, E. Acampado, A. P. Burke, K. Skorija, W. Creighton, F. D. Kolodgie, H. K. Gold, et al. Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-{beta} and MCP-1 Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 182 - 189. [Abstract] [Full Text] [PDF]

				D. Walcher, C. Babiak, P. Poletek, S. Rosenkranz, H. Bach, S. Betz, R. Durst, M. Grub, V. Hombach, J. Strong, et al. C-Peptide Induces Vascular Smooth Muscle Cell Proliferation: Involvement of Src-Kinase, Phosphatidylinositol 3-Kinase, and Extracellular Signal-Regulated Kinase 1/2 Circ. Res., November 24, 2006; 99(11): 1181 - 1187. [Abstract] [Full Text] [PDF]

				C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]

				H. Kosuge, G. Haraguchi, N. Koga, Y. Maejima, J.-i. Suzuki, and M. Isobe Pioglitazone Prevents Acute and Chronic Cardiac Allograft Rejection Circulation, June 6, 2006; 113(22): 2613 - 2622. [Abstract] [Full Text] [PDF]

				P. Iglesias and J. J Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621. [Abstract] [Full Text] [PDF]

				P. Zahradka, B. Wright, M. Fuerst, N. Yurkova, K. Molnar, and C. G. Taylor Peroxisome Proliferator-Activated Receptor {alpha} and {gamma} Ligands Differentially Affect Smooth Muscle Cell Proliferation and Migration J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 651 - 659. [Abstract] [Full Text] [PDF]

				D. Walcher, A. Kummel, B. Kehrle, H. Bach, M. Grub, R. Durst, V. Hombach, and N. Marx LXR Activation Reduces Proinflammatory Cytokine Expression in Human CD4-Positive Lymphocytes Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1022 - 1028. [Abstract] [Full Text] [PDF]

				K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A. M. Lincoff, A. M. Schmidt, E. J. Topol, et al. Peroxisome Proliferator-Activated Receptor {gamma} Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 37 - 43. [Abstract] [Full Text] [PDF]

				S. Lim, C. J. Jin, M. Kim, S. S. Chung, H. S. Park, I. K. Lee, C. T. Lee, Y. M. Cho, H. K. Lee, and K. S. Park PPAR{gamma} Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 808 - 813. [Abstract] [Full Text] [PDF]

				U. Campia, L. A. Matuskey, and J. A. Panza Peroxisome Proliferator-Activated Receptor-{gamma} Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk Factors Circulation, February 14, 2006; 113(6): 867 - 875. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]

				N. Marx, J. Wohrle, T. Nusser, D. Walcher, A. Rinker, V. Hombach, W. Koenig, and M. Hoher Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients Circulation, November 1, 2005; 112(18): 2792 - 2798. [Abstract] [Full Text] [PDF]

				N. Hennuyer, A. Tailleux, G. Torpier, H. Mezdour, J.-C. Fruchart, B. Staels, and C. Fievet PPAR{alpha}, but not PPAR{gamma}, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1897 - 1902. [Abstract] [Full Text] [PDF]

				A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1903 - 1909. [Abstract] [Full Text] [PDF]

				J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart Peroxisome Proliferator-Activated Receptor {gamma} Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Mechanisms Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1810 - 1816. [Abstract] [Full Text] [PDF]

				Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade Heart, September 1, 2005; 91(9): 1203 - 1208. [Abstract] [Full Text] [PDF]

				V. R. Babaev, P. G. Yancey, S. V. Ryzhov, V. Kon, M. D. Breyer, M. A. Magnuson, S. Fazio, and M. F. Linton Conditional Knockout of Macrophage PPAR{gamma}Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1647 - 1653. [Abstract] [Full Text] [PDF]

				V. Gaillard, D. Casellas, C. Seguin-Devaux, H. Schohn, M. Dauca, J. Atkinson, and I. Lartaud Pioglitazone Improves Aortic Wall Elasticity in a Rat Model of Elastocalcinotic Arteriosclerosis Hypertension, August 1, 2005; 46(2): 372 - 379. [Abstract] [Full Text] [PDF]

				Y. Higashi, T. Peng, J. Du, S. Sukhanov, Y. Li, H. Itabe, S. Parthasarathy, and P. Delafontaine A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor J. Lipid Res., June 1, 2005; 46(6): 1266 - 1277. [Abstract] [Full Text] [PDF]

				R. Wessely Interference by interferons: Janus faces in vascular proliferative diseases Cardiovasc Res, June 1, 2005; 66(3): 433 - 443. [Abstract] [Full Text] [PDF]

				M. Blanco, M. A. Moro, A. Davalos, R. Leira, M. Castellanos, J. Serena, J. Vivancos, M. Rodriguez-Yanez, I. Lizasoain, and J. Castillo Increased Plasma Levels of 15-Deoxy {Delta} Prostaglandin J2 Are Associated With Good Outcome in Acute Atherothrombotic Ischemic Stroke Stroke, June 1, 2005; 36(6): 1189 - 1194. [Abstract] [Full Text] [PDF]

				N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]

				A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]

				K. B. Atkins, C. A. Northcott, S. W. Watts, and F. C. Brosius Effects of PPAR-{gamma} ligands on vascular smooth muscle marker expression in hypertensive and normal arteries Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H235 - H243. [Abstract] [Full Text] [PDF]

				Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]

				L. Ragolia, T. Palaia, T. B. Koutrouby, and J. K. Maesaka Inhibition of cell cycle progression and migration of vascular smooth muscle cells by prostaglandin D2 synthase: resistance in diabetic Goto-Kakizaki rats Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1273 - C1281. [Abstract] [Full Text] [PDF]

				D. Walcher and N. Marx Insulin resistance and cardiovascular disease: the role of PPAR{gamma} activators beyond their anti-diabetic action Diabetes and Vascular Disease Research, October 1, 2004; 1(2): 76 - 81. [Abstract] [PDF]

				S. Wakino, K. Hayashi, T. Kanda, S. Tatematsu, K. Homma, K. Yoshioka, I. Takamatsu, and T. Saruta Peroxisome Proliferator-Activated Receptor {gamma} Ligands Inhibit Rho/Rho Kinase Pathway by Inducing Protein Tyrosine Phosphatase SHP-2 Circ. Res., September 3, 2004; 95(5): e45 - e55. [Abstract] [Full Text] [PDF]

				T. Temelkova-Kurktschiev, M. Hanefeld, G. Chinetti, C. Zawadzki, S. Haulon, A. Kubaszek, C. Koehler, W. Leonhardt, B. Staels, and M. Laakso Ala12Ala Genotype of the Peroxisome Proliferator-Activated Receptor {gamma}2 Protects against Atherosclerosis J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4238 - 4242. [Abstract] [Full Text] [PDF]

				B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients Diabetes Care, July 1, 2004; 27(7): 1647 - 1653. [Abstract] [Full Text] [PDF]

				H. L. Keen, M. J. Ryan, A. Beyer, S. Mathur, T. E. Scheetz, B. D. Gackle, F. M. Faraci, T. L. Casavant, and C. D. Sigmund Gene expression profiling of potential PPAR{gamma} target genes in mouse aorta Physiol Genomics, June 17, 2004; 18(1): 33 - 42. [Abstract] [Full Text] [PDF]

				R. Cunard, Y. Eto, J. T. Muljadi, C. K. Glass, C. J. Kelly, and M. Ricote Repression of IFN-{gamma} Expression by Peroxisome Proliferator-Activated Receptor {gamma} J. Immunol., June 15, 2004; 172(12): 7530 - 7536. [Abstract] [Full Text] [PDF]

				A. Natali, S. Baldeweg, E. Toschi, B. Capaldo, D. Barbaro, A. Gastaldelli, J. S. Yudkin, and E. Ferrannini Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1349 - 1357. [Abstract] [Full Text] [PDF]

				N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]

				F. Cipollone, M. Fazia, A. Iezzi, B. Pini, C. Cuccurullo, M. Zucchelli, D. de Cesare, S. Ucchino, F. Spigonardo, M. De Luca, et al. Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2-Dependent Matrix Metalloproteinase Activity Circulation, March 30, 2004; 109(12): 1482 - 1488. [Abstract] [Full Text] [PDF]

				M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund PPAR{gamma} Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice Hypertension, March 1, 2004; 43(3): 661 - 666. [Abstract] [Full Text] [PDF]

				Y. Lin, X. Zhu, F. L. Mclntee, H. Xiao, J. Zhang, M. Fu, and Y. E. Chen Interferon Regulatory Factor-1 Mediates PPAR{gamma}-Induced Apoptosis in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 257 - 263. [Abstract] [Full Text]

				W. A. Hsueh and D. Bruemmer Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease Hypertension, February 1, 2004; 43(2): 297 - 305. [Abstract] [Full Text] [PDF]

				J. R. Worley, M. D. Baugh, D. A. Hughes, D. R. Edwards, A. Hogan, M. J. Sampson, and J. Gavrilovic Metalloproteinase Expression in PMA-stimulated THP-1 Cells: EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} (PPAR{gamma}) AGONISTS AND 9-CIS-RETINOIC ACID J. Biol. Chem., December 19, 2003; 278(51): 51340 - 51346. [Abstract] [Full Text] [PDF]

				C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 297 - 305. [Abstract] [PDF]

				J. W. Phillips, K. G. Barringhaus, J. M. Sanders, Z. Yang, M. Chen, S. Hesselbacher, A. C. Czarnik, K. Ley, J. Nadler, and I. J. Sarembock Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 Diabetes Circulation, October 21, 2003; 108(16): 1994 - 1999. [Abstract] [Full Text] [PDF]

				B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF]

				P. Meerarani, G. Reiterer, M. Toborek, and B. Hennig Zinc Modulates PPAR{gamma} Signaling and Activation of Porcine Endothelial Cells J. Nutr., October 1, 2003; 133(10): 3058 - 3064. [Abstract] [Full Text] [PDF]

				C. B Jones, D. C Sane, and D. M Herrington Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome Cardiovasc Res, October 1, 2003; 59(4): 812 - 823. [Abstract] [Full Text] [PDF]

				M. Iglarz, R. M. Touyz, E. C. Viel, P. Paradis, F. Amiri, Q. N. Diep, and E. L. Schiffrin Peroxisome Proliferator-Activated Receptor-{alpha} and Receptor-{gamma} Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension Hypertension, October 1, 2003; 42(4): 737 - 743. [Abstract] [Full Text] [PDF]

				M. Mendez and M. C. LaPointe PPAR{gamma} Inhibition of Cyclooxygenase-2, PGE2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes Hypertension, October 1, 2003; 42(4): 844 - 850. [Abstract] [Full Text] [PDF]

				N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, H. Uesugi, H. Sugiyama, A. Sugawara, K. Yamada, A. Shimatsu, et al. Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect Diabetes Care, September 1, 2003; 26(9): 2493 - 2499. [Abstract] [Full Text] [PDF]

				M Hetzel, D Walcher, M Grub, H Bach, V Hombach, and N Marx Inhibition of MMP-9 expression by PPAR{gamma} activators in human bronchial epithelial cells Thorax, September 1, 2003; 58(9): 778 - 783. [Abstract] [Full Text] [PDF]

				Z. Yuan, Y. Liu, Y. Liu, J. Zhang, C. Kishimoto, Y. Wang, A. Ma, and Z. Liu Peroxisome proliferation-activated receptor-{gamma} ligands ameliorate experimental autoimmune myocarditis Cardiovasc Res, September 1, 2003; 59(3): 685 - 694. [Abstract] [Full Text] [PDF]

				D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Sakai, F. Blaschke, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor {gamma} in Vascular Smooth Muscle Cells Circ. Res., August 22, 2003; 93 (4): e38 - e47. [Abstract] [Full Text] [PDF]

				Y. Taba, M. Miyagi, Y. Miwa, H. Inoue, F. Takahashi-Yanaga, S. Morimoto, and T. Sasaguri 15-Deoxy-{Delta}12,14-prostaglandin J2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H38 - H46. [Abstract] [Full Text] [PDF]

				K.-H. Mak and D. P. Faxon Clinical studies on coronary revascularization in patients with type 2 diabetes Eur. Heart J., June 2, 2003; 24(12): 1087 - 1103. [Abstract] [Full Text] [PDF]

				D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Kiyono, J. Chen, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law Peroxisome Proliferator-Activated Receptor {gamma} Inhibits Expression of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells Mol. Endocrinol., June 1, 2003; 17(6): 1005 - 1018. [Abstract] [Full Text] [PDF]

				J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages PNAS, May 27, 2003; 100(11): 6712 - 6717. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Inflammation and Insulin Resistance Diabetes Care, May 1, 2003; 26(5): 1619 - 1623. [Full Text] [PDF]

				F. Zangeneh, Y. C. Kudva, and A. Basu Insulin Sensitizers Mayo Clin. Proc., April 1, 2003; 78(4): 471 - 479. [Abstract] [PDF]

				N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 283 - 288. [Abstract] [Full Text] [PDF]

				J. Martinez-Gonzalez, J. Rius, A. Castello, C. Cases-Langhoff, and L. Badimon Neuron-Derived Orphan Receptor-1 (NOR-1) Modulates Vascular Smooth Muscle Cell Proliferation Circ. Res., January 10, 2003; 92(1): 96 - 103. [Abstract] [Full Text] [PDF]

				M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin Effect of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Activators on Vascular Remodeling in Endothelin-Dependent Hypertension Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 45 - 51. [Abstract] [Full Text] [PDF]

				T. Shiomi, H. Tsutsui, S. Hayashidani, N. Suematsu, M. Ikeuchi, J. Wen, M. Ishibashi, T. Kubota, K. Egashira, and A. Takeshita Pioglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction Circulation, December 10, 2002; 106(24): 3126 - 3132. [Abstract] [Full Text] [PDF]

				U. Kintscher, C. Lyon, S. Wakino, D. Bruemmer, X. Feng, S. Goetze, K. Graf, A. Moustakas, B. Staels, E. Fleck, et al. PPAR{alpha} Inhibits TGF-{beta}-Induced {beta}5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4 Circ. Res., November 29, 2002; 91 (11): e35 - e44. [Abstract] [Full Text] [PDF]

				Z.-W. Hu, R. Kerb, X.-Y. Shi, T. Wei-Lavery, and B. B. Hoffman Angiotensin II Increases Expression of Cyclooxygenase-2: Implications for the Function of Vascular Smooth Muscle Cells J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 563 - 573. [Abstract] [Full Text] [PDF]

				C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF]

				M. Ishibashi, K. Egashira, K.-i. Hiasa, S. Inoue, W. Ni, Q. Zhao, M. Usui, S. Kitamoto, T. Ichiki, and A. Takeshita Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone Hypertension, November 1, 2002; 40(5): 687 - 693. [Abstract] [Full Text] [PDF]

				S. Goetze, A. Bungenstock, C. Czupalla, F. Eilers, P. Stawowy, U. Kintscher, C. Spencer-Hansch, K. Graf, B. Nurnberg, R. E. Law, et al. Leptin Induces Endothelial Cell Migration Through Akt, Which Is Inhibited by PPAR{gamma}-Ligands Hypertension, November 1, 2002; 40(5): 748 - 754. [Abstract] [Full Text] [PDF]

				Y. Sakomura, H. Nagashima, Y. Aoka, K. Uto, A. Sakuta, S. Aomi, H. Kurosawa, T. Nishikawa, and H. Kasanuki Expression of Peroxisome Proliferator-Activated Receptor-{gamma} in Vascular Smooth Muscle Cells Is Upregulated in Cystic Medial Degeneration of Annuloaortic Ectasia in Marfan Syndrome Circulation, September 24, 2002; 106(12_suppl_1): I-259 - I-263. [Abstract] [Full Text] [PDF]

				E. Cernuda-Morollon, F. Rodriguez-Pascual, P. Klatt, S. Lamas, and D. Perez-Sala PPAR Agonists Amplify iNOS Expression While Inhibiting NF-{kappa}B: Implications for Mesangial Cell Activation by Cytokines J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2223 - 2231. [Abstract] [Full Text] [PDF]

				D. Bishop-Bailey, T. Hla, and T. D. Warner Intimal Smooth Muscle Cells as a Target for Peroxisome Proliferator-Activated Receptor-{gamma} Ligand Therapy Circ. Res., August 9, 2002; 91(3): 210 - 217. [Abstract] [Full Text] [PDF]

				S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus Circulation, August 6, 2002; 106(6): 679 - 684. [Abstract] [Full Text] [PDF]

				P. A. Watson, C. Vinson, A. Nesterova, and J. E.-B. Reusch Content and Activity of cAMP Response Element-Binding Protein Regulate Platelet-Derived Growth Factor Receptor-{alpha} Content in Vascular Smooth Muscles Endocrinology, August 1, 2002; 143(8): 2922 - 2929. [Abstract] [Full Text] [PDF]

				Q. N. Diep, M. El Mabrouk, J. S. Cohn, D. Endemann, F. Amiri, A. Virdis, M. F. Neves, and E. L. Schiffrin Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II-Infused Rats: Role of Peroxisome Proliferator-Activated Receptor-{gamma} Circulation, May 14, 2002; 105(19): 2296 - 2302. [Abstract] [Full Text] [PDF]

				C. M. Komar and T. E. Curry Jr Localization and Expression of Messenger RNAs for the Peroxisome Proliferator-Activated Receptors in Ovarian Tissue from Naturally Cycling and Pseudopregnant Rats Biol Reprod, May 1, 2002; 66(5): 1531 - 1539. [Abstract] [Full Text]

				N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig, V. Hombach, P. Libby, and J. Plutzky PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis Circ. Res., April 5, 2002; 90(6): 703 - 710. [Abstract] [Full Text] [PDF]

				A. Sugawara, A. Uruno, M. Kudo, Y. Ikeda, K. Sato, Y. Taniyama, S. Ito, and K. Takeuchi Transcription Suppression of Thromboxane Receptor Gene by Peroxisome Proliferator-activated Receptor-gamma via an Interaction with Sp1 in Vascular Smooth Muscle Cells J. Biol. Chem., March 15, 2002; 277(12): 9676 - 9683. [Abstract] [Full Text] [PDF]

				T. Shibata, M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida 15-Deoxy-Delta 12,14-prostaglandin J2. A PROSTAGLANDIN D2 METABOLITE GENERATED DURING INFLAMMATORY PROCESSES J. Biol. Chem., March 15, 2002; 277(12): 10459 - 10466. [Abstract] [Full Text] [PDF]

				N. Frey and E. N. Olson Modulating Cardiac Hypertrophy by Manipulating Myocardial Lipid Metabolism? Circulation, March 12, 2002; 105(10): 1152 - 1154. [Full Text] [PDF]

				B. Molavi, N. Rasouli, and J. L. Mehta Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box? Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 1 - 8. [Abstract] [PDF]

				A. Diab, C. Deng, J. D. Smith, R. Z. Hussain, B. Phanavanh, A. E. Lovett-Racke, P. D. Drew, and M. K. Racke Peroxisome Proliferator-Activated Receptor-{gamma} Agonist 15-Deoxy-{Delta}12,1412,14-Prostaglandin J2 Ameliorates Experimental Autoimmune Encephalomyelitis J. Immunol., March 1, 2002; 168(5): 2508 - 2515. [Abstract] [Full Text] [PDF]

				Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi PPAR{gamma} Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells Circ. Res., February 22, 2002; 90(3): 348 - 355. [Abstract] [Full Text] [PDF]

				B. R. Kwak, S. Myit, F. Mulhaupt, N. Veillard, N. Rufer, E. Roosnek, and F. Mach PPAR{gamma} but not PPAR{alpha} Ligands Are Potent Repressors of Major Histocompatibility Complex Class II Induction in Atheroma-Associated Cells Circ. Res., February 22, 2002; 90(3): 356 - 362. [Abstract] [Full Text] [PDF]

				S. Arima, K. Kohagura, K. Takeuchi, Y. Taniyama, A. Sugawara, Y. Ikeda, M. Abe, K. Omata, and S. Ito Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 342 - 349. [Abstract] [Full Text] [PDF]

				W. A. Hsueh and R. E. Law PPAR{gamma} and Atherosclerosis: Effects on Cell Growth and Movement Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1891 - 1895. [Abstract] [Full Text] [PDF]

				M. Fu, J. Zhang, X. Zhu, D. E. Myles, T. M. Willson, X. Liu, and Y. E. Chen Peroxisome Proliferator-activated Receptor gamma Inhibits Transforming Growth Factor beta -induced Connective Tissue Growth Factor Expression in Human Aortic Smooth Muscle Cells by Interfering with Smad3 J. Biol. Chem., November 30, 2001; 276(49): 45888 - 45894. [Abstract] [Full Text] [PDF]

				D. P. Kelly The Pleiotropic Nature of the Vascular PPAR Gene Regulatory Pathway Circ. Res., November 23, 2001; 89(11): 935 - 937. [Full Text] [PDF]

				C. M. Komar, O. Braissant, W. Wahli, and T. E. Curry Jr. Expression and Localization of PPARs in the Rat Ovary During Follicular Development and the Periovulatory Period Endocrinology, November 1, 2001; 142(11): 4831 - 4838. [Abstract] [Full Text] [PDF]

				L. BENAYOUN, S. LETUVE, A. DRUILHE, J. BOCZKOWSKI, M.-C. DOMBRET, P. MECHIGHEL, J. MEGRET, G. LESECHE, M. AUBIER, and M. PRETOLANI Regulation of Peroxisome Proliferator-activated Receptor gamma Expression in Human Asthmatic Airways . Relationship with Proliferation, Apoptosis, and Airway Remodeling Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1487 - 1494. [Abstract] [Full Text] [PDF]

				A. Tarrade, K. Schoonjans, L. Pavan, J. Auwerx, C. Rochette-Egly, D. Evain-Brion, and T. Fournier PPAR{gamma}/RXR{alpha} Heterodimers Control Human Trophoblast Invasion J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5017 - 5024. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marx, N. Articles by Plutzky, J. Search for Related Content PubMed PubMed Citation Articles by Marx, N. Articles by Plutzky, J.